Search

Your search keyword '"Federico, Argüelles-Arias"' showing total 118 results

Search Constraints

Start Over You searched for: Author "Federico, Argüelles-Arias" Remove constraint Author: "Federico, Argüelles-Arias" Language undetermined Remove constraint Language: undetermined
Sorry, I don't understand your search. ×
118 results on '"Federico, Argüelles-Arias"'

Search Results

1. Clinical utility of urinary gluten immunogenic peptides in the follow‐up of patients with coeliac disease

2. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

Catalog

Books, media, physical & digital resources

4. sj-docx-2-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

5. sj-docx-3-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

6. sj-docx-3-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

7. sj-docx-2-tag-10.1177_17562848231153560 – Supplemental material for Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study

12. Perianal Paget's disease

13. Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study

20. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn's Disease Patients on Ustekinumab

21. COST-EFFECTIVENESS ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SPAIN

22. Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results

23. Cost-effectiveness analysis of ferric carboxymaltose

25. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori

26. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFα used for the treatment of IBD: Results from the VERNE study

27. New therapies for inflammatory bowel diseases

28. Ustekinumab in Crohn's disease: real-world outcomes and predictors of response

29. Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results

30. Polyphenolic Maqui Extract as a Potential Nutraceutical to Treat TNBS-Induced Crohn's Disease by the Regulation of Antioxidant and Anti-Inflammatory Pathways

31. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

32. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease

33. DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

34. P478 Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study

36. Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

37. Cut-off ranges of infliximab serum levels in Crohn�s disease in the clinical practice

38. National survey on the experiences of people with celiac disease in Spain. The CELIAC-SPAIN project

39. Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results

40. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry

41. Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations

42. BEWARE OF THE GLUE

43. Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome

45. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

46. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain

47. Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?

48. Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal

50. Influence of age, body mass index and comorbidity on major outcomes in acute pancreatitis, a prospective nation-wide multicentre study